



Financial Tear Sheet

Corporate Profile

Codexis, Inc. (Nasdaq: CDXS), is a leading developer of biocatalysts for the pharmaceutical and fine chemical industries. Codexis utilizes its proprietary CodeEvolver® directed evolution technology platform and CodeXporter® enzyme production platform, for the discovery, identification, optimization, and efficient production of enzymes for its customers. Customers include global leaders such as Merck, Pfizer and Teva. For more information, see www.codexis.com

Stock Performance

CDXS (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$3.82
Change (%)	▲ 0.31 (8.83%)
Volume	300,651
52 Week Low	\$1.34
Market Cap	\$151,077,180
Rolling EPS	-0.76
PE Ratio	N/A
Shares Outstanding	39,549,000

Data as of 01/30/15 4:00 p.m. ET



Recent News Releases

December 03, 2014

[Codexis Uses Its CodeEvolver\(R\) Protein Engineering Platform Technology to Develop an Enzyme Therapeutic Candidate for the Potential Treatment of Phenylketonuria \(PKU\) via Oral Administration](#)

November 25, 2014

[Codexis to Present at the LD Micro Main Event VII Conference on December 4](#)

November 04, 2014

[Codexis Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2014](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
01/30/15	SC 13G
12/22/14	4/A
11/20/14	4
11/19/14	4

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed